

Elias A Mossialos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1756108/publications.pdf>

Version: 2024-02-01

277
papers

9,696
citations

47006

47
h-index

56724

83
g-index

291
all docs

291
docs citations

291
times ranked

11708
citing authors

#	ARTICLE	IF	CITATIONS
1	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020, 41, 12-85.	2.2	690
2	The primary health-care system in China. <i>Lancet, The</i> , 2017, 390, 2584-2594.	13.7	609
3	The impact of the COVID-19 pandemic on cancer care. <i>Nature Cancer</i> , 2020, 1, 565-567.	13.2	392
4	Quality of primary health care in China: challenges and recommendations. <i>Lancet, The</i> , 2020, 395, 1802-1812.	13.7	391
5	European Society of Cardiology: cardiovascular disease statistics 2021. <i>European Heart Journal</i> , 2022, 43, 716-799.	2.2	343
6	Equity of access to health care: outlining the foundations for action. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 655-658.	3.7	318
7	From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management. <i>Health Policy</i> , 2015, 119, 628-639.	3.0	294
8	COVID-19 vaccine challenges: What have we learned so far and what remains to be done?. <i>Health Policy</i> , 2021, 125, 553-567.	3.0	199
9	Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. <i>Journal of Antibiotics</i> , 2017, 70, 1087-1096.	2.0	171
10	A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. <i>Journal of Antibiotics</i> , 2016, 69, 73-88.	2.0	152
11	Analysing the Greek health system: a tale of fragmentation and inertia. <i>Health Economics (United Kingdom)</i> 17(1): 142-152	1.7	142
12	12 Lessons learned from the management of the coronavirus pandemic. <i>Health Policy</i> , 2020, 124, 577-580.	3.0	137
13	Citizens' Views on Health Care Systems in the 15 Member States of The European Union. , 1997, 6, 109-116.		126
14	Health technology assessment and its influence on health-care priority setting. <i>International Journal of Technology Assessment in Health Care</i> , 2004, 20, 1-10.	0.5	115
15	Measuring Socioeconomic Differences in Use of Health Care Services by Wealth Versus by Income. <i>American Journal of Public Health</i> , 2009, 99, 1849-1855.	2.7	114
16	Health information technology and digital innovation for national learning health and care systems. <i>The Lancet Digital Health</i> , 2021, 3, e383-e396.	12.3	107
17	Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines. <i>JAMA Oncology</i> , 2017, 3, 382.	7.1	105
18	Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. <i>Lancet, The</i> , 2017, 390, 2559-2568.	13.7	103

#	ARTICLE	IF	CITATIONS
19	Cost containment and health care reform: a study of the European Union. Health Policy, 1994, 28, 89-132.	3.0	102
20	Mapping support policies for informal carers across the European Union. Health Policy, 2014, 118, 84-94.	3.0	100
21	Does organ donation legislation affect individuals' willingness to donate their own or their relative's organs? Evidence from European Union survey data. BMC Health Services Research, 2008, 8, 48.	2.2	96
22	Stoking the antibiotic pipeline. BMJ: British Medical Journal, 2010, 340, c2115-c2115.	2.3	92
23	A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility. Globalization and Health, 2016, 12, 8.	4.9	90
24	Strategies for achieving global collective action on antimicrobial resistance. Bulletin of the World Health Organization, 2015, 93, 867-876.	3.3	90
25	Citizens and rationing: analysis of a European survey. Health Policy, 1999, 49, 75-135.	3.0	82
26	Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence?. Health Policy, 2013, 111, 135-148.	3.0	78
27	Voluntary Health Insurance in the European Union: A Critical Assessment. International Journal of Health Services, 2002, 32, 19-88.	2.5	75
28	Crowdfunding our health: Economic risks and benefits. Social Science and Medicine, 2017, 191, 48-56.	3.8	75
29	Covid-19 exposes weaknesses in European response to outbreaks. BMJ, The, 2020, 368, m1075.	6.0	73
30	European Health Systems Reforms: Looking Backward to See Forward?. Journal of Health Politics, Policy and Law, 2005, 30, 7-28.	1.9	70
31	Does health insurance reduce out-of-pocket expenditure? Heterogeneity among China's middle-aged and elderly. Social Science and Medicine, 2017, 190, 11-19.	3.8	68
32	Implementation of Transcatheter Aortic Valve Replacement in France. Journal of the American College of Cardiology, 2018, 71, 1614-1627.	2.8	68
33	Resurgence of covid-19 in Japan. BMJ, The, 2020, 370, m3221.	6.0	67
34	Financing institutional long-term care for the elderly in China: a policy evaluation of new models. Health Policy and Planning, 2016, 31, 1391-1401.	2.7	66
35	Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts. Health Policy, 2016, 120, 519-534.	3.0	65
36	The Determinants of Private Medical Insurance Prevalence in England, 1997-2000. Health Services Research, 2005, 40, 195-212.	2.0	64

#	ARTICLE	IF	CITATIONS
37	Health system, public health, and economic implications of managing COVID-19 from a cardiovascular perspective. <i>European Heart Journal</i> , 2020, 41, 2516-2518.	2.2	64
38	Securing a sustainable and fit-for-purpose UK health and care workforce. <i>Lancet, The</i> , 2021, 397, 1992-2011.	13.7	64
39	A governance framework for development and assessment of national action plans on antimicrobial resistance. <i>Lancet Infectious Diseases, The</i> , 2019, 19, e371-e384.	9.1	62
40	Investing in health R&D: where we are, what limits us, and how to make progress in Africa. <i>BMJ Global Health</i> , 2019, 4, e001047.	4.7	62
41	The Relationship Between the COVID-19 Pandemic and Vaccine Hesitancy: A Scoping Review of Literature Until August 2021. <i>Frontiers in Public Health</i> , 2021, 9, 747787.	2.7	62
42	Antibiotic research and development: business as usual?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1604-7.	3.0	60
43	Choice of public or private health insurance: learning from the experience of Germany and the Netherlands. <i>Journal of European Social Policy</i> , 2006, 16, 315-327.	2.8	57
44	Performance of UK National Health Service compared with other high income countries: observational study. <i>BMJ, The</i> , 2019, 367, l6326.	6.0	57
45	Optimism and the perceptions of new risks. <i>Journal of Risk Research</i> , 2009, 12, 27-41.	2.6	56
46	Are perceptions of "risks" and "benefits" of genetically modified food (in)dependent?. <i>Food Quality and Preference</i> , 2007, 18, 173-182.	4.6	55
47	An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. <i>International Journal of Health Planning and Management</i> , 2005, 20, 291-306.	1.7	53
48	What are the essential features of a successful surgical registry? a systematic review. <i>BMJ Open</i> , 2017, 7, e017373.	1.9	53
49	Plus Ça Change : Health Sector Reforms in Greece. <i>Journal of Health Politics, Policy and Law</i> , 2005, 30, 143-168.	1.9	51
50	Attitudes as an Expression of Knowledge and "Political Anchoring": The Case of Nuclear Power in the United Kingdom. <i>Risk Analysis</i> , 2008, 28, 1273-1288.	2.7	50
51	A Conceptual Framework for Community-Based Health Insurance in Low-Income Countries: Social Capital and Economic Development. <i>World Development</i> , 2008, 36, 590-607.	4.9	50
52	LSE "Lancet Commission on the future of the NHS: re-laying the foundations for an equitable and efficient health and care service after COVID-19. <i>Lancet, The</i> , 2021, 397, 1915-1978.	13.7	49
53	Digital Health Paradox: International Policy Perspectives to Address Increased Health Inequalities for People Living With Disabilities. <i>Journal of Medical Internet Research</i> , 2022, 24, e33819.	4.3	49
54	Health impacts of the Russian invasion in Ukraine: need for global health action. <i>Lancet, The</i> , 2022, 399, 1450-1452.	13.7	45

#	ARTICLE	IF	CITATIONS
55	The diabetes-obesity-hypertension nexus in Qatar: evidence from the World Health Survey. <i>Population Health Metrics</i> , 2014, 12, 18.	2.7	43
56	Big Data and Health Care: Challenges and Opportunities for Coordinated Policy Development in the EU. <i>Health Systems and Reform</i> , 2015, 1, 285-300.	1.2	41
57	Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. <i>EClinicalMedicine</i> , 2021, 42, 101198.	7.1	40
58	Stimulating pharmaceutical research and development for neglected diseases. <i>Health Policy</i> , 2003, 64, 75-88.	3.0	38
59	Constitutional asymmetry and pharmaceutical policy-making in the European Union. <i>Journal of European Public Policy</i> , 2005, 12, 687-709.	4.0	37
60	What are the economic barriers of antibiotic R&D and how can we overcome them?. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 889-892.	5.0	37
61	Regulating Private Health Insurance in the European Union: The Implications of Single Market Legislation and Competition Policy. <i>Journal of European Integration</i> , 2007, 29, 89-107.	2.1	36
62	Physician Density by Specialty Type in Urban and Rural Counties in the US, 2010 to 2017. <i>JAMA Network Open</i> , 2021, 4, e2033994.	5.9	36
63	Developing a sustainable exit strategy for COVID-19: health, economic and public policy implications. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 176-178.	2.0	35
64	Can user charges make health care more efficient?. <i>BMJ: British Medical Journal</i> , 2010, 341, c3759-c3759.	2.3	35
65	Interest Groups and Health System Reform in Greece. <i>West European Politics</i> , 2005, 28, 420-444.	4.7	34
66	The EU's new paediatric medicines legislation: serving children's needs?. <i>Archives of Disease in Childhood</i> , 2007, 92, 808-811.	1.9	34
67	Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model. <i>Globalization and Health</i> , 2013, 9, 58.	4.9	34
68	Why the drug development pipeline is not delivering better medicines. <i>BMJ, The</i> , 2015, 351, h5542.	6.0	34
69	Social determinants of health and obesity: Findings from a national study of US adults. <i>Obesity</i> , 2022, 30, 491-502.	3.0	34
70	International Comparisons of Health Care Expenditures: What We Know and What We Do not Know. <i>Journal of Health Services Research and Policy</i> , 1999, 4, 122-126.	1.7	33
71	Physician revalidation in Europe. <i>Clinical Medicine</i> , 2008, 8, 371-376.	1.9	32
72	Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval. <i>JAMA Internal Medicine</i> , 2021, 181, 490.	5.1	32

#	ARTICLE	IF	CITATIONS
73	Equity in health care use among older people in the UK: an analysis of panel data. <i>Applied Economics</i> , 2011, 43, 2229-2239.	2.2	30
74	Is there "patient selection" in the demand for private maternity care in Greece?. <i>Applied Economics Letters</i> , 2005, 12, 7-12.	1.8	29
75	How primary health care can make universal health coverage a reality, ensure healthy lives, and promote wellbeing for all. <i>Lancet, The</i> , 2018, 392, 1372-1374.	13.7	29
76	European Society of Cardiology: cardiovascular disease statistics 2021: Executive Summary. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 377-382.	4.0	29
77	Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. <i>Social Science and Medicine</i> , 2020, 258, 113042.	3.8	28
78	Inequality in healthcare use among older people in Colombia. <i>International Journal for Equity in Health</i> , 2020, 19, 168.	3.5	27
79	Pharmaceutical Expenditure in Spain: Cost and Control. <i>International Journal of Health Services</i> , 2000, 30, 597-616.	2.5	26
80	Analysis Of End-Of-Life Care, Out-Of-Pocket Spending, And Place Of Death In 16 European Countries And Israel. <i>Health Affairs</i> , 2017, 36, 1201-1210.	5.2	26
81	Is dread of Genetically Modified food associated with the consumers' demand for information?. <i>Applied Economics Letters</i> , 2005, 12, 859-863.	1.8	25
82	Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. <i>International Journal of Health Planning and Management</i> , 2005, 20, 375-398.	1.7	25
83	The Public as a Limit to Technology Transfer: The Influence of Knowledge and Beliefs in Attitudes towards Biotechnology in the UK. <i>Journal of Technology Transfer</i> , 2006, 31, 629-645.	4.3	25
84	Health care and the EU: the law and policy patchwork. , 2010, , 84-133.		25
85	Commissioning for equity in the NHS: rhetoric and practice. <i>British Medical Bulletin</i> , 2015, 115, 5-17.	6.9	25
86	A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. <i>Health Policy</i> , 2016, 120, 1104-1114.	3.0	25
87	A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. <i>Journal of Clinical Epidemiology</i> , 2019, 105, 50-59.	5.0	25
88	Effectiveness of government policies in response to the first COVID-19 outbreak. <i>PLOS Global Public Health</i> , 2022, 2, e0000242.	1.6	25
89	A pricing policy towards the sourcing of cheaper drugs in Cyprus. <i>Health Policy</i> , 2007, 81, 368-375.	3.0	24
90	Cancer Drugs Provide Positive Value In Nine Countries, But The United States Lags In Health Gains Per Dollar Spent. <i>Health Affairs</i> , 2016, 35, 813-823.	5.2	24

#	ARTICLE	IF	CITATIONS
91	Malaria and Macronutrient Deficiency as Correlates of Anemia in Young Children: A Systematic Review of Observational Studies. <i>Annals of Global Health</i> , 2018, 80, 458.	2.0	24
92	Drawing light from the pandemic: Rethinking strategies for health policy and beyond. <i>Health Policy</i> , 2022, 126, 1-6.	3.0	24
93	Prices For Cardiac Implant Devices May Be Up To Six Times Higher In The US Than In Some European Countries. <i>Health Affairs</i> , 2018, 37, 1570-1577.	5.2	23
94	Beyond gross domestic product for New Zealand's wellbeing budget. <i>Lancet Public Health</i> , The, 2019, 4, e320-e321.	10.0	23
95	The UK needs a sustainable strategy for COVID-19. <i>Lancet</i> , The, 2020, 396, 1800-1801.	13.7	23
96	Patient Choice of Health Care Providers in China: Primary Care Facilities versus Hospitals. <i>Health Systems and Reform</i> , 2020, 6, e1846844.	1.2	23
97	Public procurement and state aid in national health care systems. , 0, , 379-418.		22
98	Health policy in times of austerityâ€™A conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008. <i>Health Policy</i> , 2017, 121, 947-954.	3.0	22
99	Rebuilding the broken health contract in Chile. <i>Lancet</i> , The, 2020, 395, 1342.	13.7	22
100	COVID-19 vaccine mandate for healthcare workers in the United States: a social justice policy. <i>Expert Review of Vaccines</i> , 2022, 21, 37-45.	4.4	22
101	The Level Of Income Appears To Have No Consistent Bearing On Pharmaceutical Prices Across Countries. <i>Health Affairs</i> , 2011, 30, 1545-1552.	5.2	21
102	Effectiveness of UK provider financial incentives on quality of care: a systematic review. <i>British Journal of General Practice</i> , 2017, 67, e800-e815.	1.4	21
103	Virtual primary care: fragmentation or integration?. <i>The Lancet Digital Health</i> , 2019, 1, e330-e331.	12.3	21
104	Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England. <i>EClinicalMedicine</i> , 2020, 29-30, 100625.	7.1	21
105	Outstanding Regulatory Aspects in the European Pharmaceutical Market. <i>Pharmacoeconomics</i> , 1999, 15, 519-533.	3.3	20
106	The EU Response to COVIDâ€™19: From Reactive Policies to Strategic Decisionâ€™Making. <i>Journal of Common Market Studies</i> , 2021, 59, 56-68.	2.1	20
107	â€™Ambivalentâ€™™ individual preferences towards biotechnology in the European Union: products or processes?. <i>Journal of Risk Research</i> , 2005, 8, 341-354.	2.6	19
108	Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance. <i>Clinical Medicine</i> , 2006, 6, 87-90.	1.9	19

#	ARTICLE	IF	CITATIONS
109	The hard politics of soft law: the case of health. , 2010, , 186-230.		18
110	What are the requirements for developing a successful national registry of auditory implants? A qualitative study. <i>BMJ Open</i> , 2018, 8, e021720.	1.9	18
111	Does economic recession impact newborn health? Evidence from Greece. <i>Social Science and Medicine</i> , 2019, 237, 112451.	3.8	18
112	Enabling patient mobility in the EU: between free movement and coordination. , 0, , 509-560.		17
113	Equity of access to maternal health interventions in Brazil and Colombia: a retrospective study. <i>International Journal for Equity in Health</i> , 2018, 17, 43.	3.5	17
114	Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. <i>Vaccine</i> , 2020, 38, 6075-6077.	3.8	17
115	Social Determinants of Disparities in Mortality Outcomes in Congenital Heart Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 829902.	2.4	17
116	Free movement of services in the EU and health care. , 2010, , 461-508.		16
117	Public health policies. , 2010, , 231-281.		16
118	Health systems responsiveness: a measure of the acceptability of health-care processes and systems from the user's perspective. , 2010, , 138-186.		16
119	After Astana: building the economic case for increased investment in primary health care. <i>Lancet, The</i> , 2018, 392, 2147-2152.	13.7	16
120	Membership In Seguro Popular In Mexico Linked To A Small Reduction In Catastrophic Health Expenditure. <i>Health Affairs</i> , 2018, 37, 1169-1177.	5.2	16
121	Self-reported Symptoms of Depression Among Chinese Rural-to-Urban Migrants and Left-Behind Family Members. <i>JAMA Network Open</i> , 2019, 2, e193355.	5.9	16
122	It's not ageing, stupid: why population ageing won't bankrupt health systems. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 195-201.	4.0	16
123	For-Profit Hospitals Have Thrived Because of Generous Public Reimbursement Schemes, Not Greater Efficiency: A Multi-Country Case Study. <i>International Journal of Health Services</i> , 2021, 51, 67-89.	2.5	16
124	A new strategy for health and sustainable development in the light of the COVID-19 pandemic. <i>Lancet, The</i> , 2021, 398, 1029-1031.	13.7	16
125	The European Health Data Space fails to bridge digital divides. <i>BMJ, The</i> , 0, , e071913.	6.0	16
126	When is the Internet a valued communication device for health information in Europe?. <i>Economics of Innovation and New Technology</i> , 2009, 18, 429-445.	3.4	15

#	ARTICLE	IF	CITATIONS
127	Private health insurance and the internal market. , 0, , 419-460.		15
128	Brexit and the NHS: Challenges, uncertainties and opportunities. Health Policy, 2017, 121, 477-480.	3.0	15
129	Estimating the incidence and the economic burden of third and fourth-degree obstetric tears in the English NHS: an observational study using propensity score matching. BMJ Open, 2017, 7, e015463.	1.9	15
130	Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs. Value in Health, 2020, 23, 319-327.	0.3	15
131	What is the right level of spending needed for health and care in the UK?. Lancet, The, 2021, 397, 2012-2022.	13.7	15
132	Divergent vaccination policies could fuel mistrust and hesitancy. Lancet, The, 2021, 397, 2333.	13.7	15
133	Navigating the role of the EU Health Emergency Preparedness and Response Authority (HERA) in Europe and beyond. Lancet Regional Health - Europe, The, 2021, 9, 100203.	5.6	15
134	Pharmaceutical Pricing in Europe: Weighing up the Options. International Social Security Review, 2006, 59, 3-25.	0.8	14
135	Applying the concepts of financial options to stimulate vaccine development. Nature Reviews Drug Discovery, 2006, 5, 641-647.	46.4	14
136	The Economics of Health Care Delivery. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 482-488.	1.8	14
137	Behavioral adjustment to avian flu in Europe during spring 2006: The roles of knowledge and proximity to risk. Social Science and Medicine, 2012, 75, 1362-1371.	3.8	14
138	Has the Portuguese NHS Achieved its Objectives of Equity and Efficiency?. International Social Security Review, 2000, 53, 49-78.	0.8	13
139	Health systems governance in Europe: the role of European Union law and policy. , 0, , 1-83.		13
140	The impact of the Greek economic adjustment programme on household health expenditure. Social Science and Medicine, 2019, 222, 274-284.	3.8	13
141	The relationship between off-hours admissions for primary percutaneous coronary intervention, door-to-balloon time and mortality for patients with ST-elevation myocardial infarction in England: a registry-based prospective national cohort study. BMJ Quality and Safety, 2020, 29, 541-549.	3.7	13
142	A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective. Journal of Heart and Lung Transplantation, 2022, 41, 174-186.	0.6	13
143	Provider incentives and prescribing behavior in Europe. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 81-93.	1.4	12
144	Measuring financial protection in health. , 0, , 114-137.		12

#	ARTICLE	IF	CITATIONS
145	Fundamental rights and health care. , 2010, , 282-314.		12
146	The EU legal framework on e-health. , 2010, , 561-588.		12
147	Balancing economic freedom against social policy principles: EC competition law and national health systems. Health Policy, 2012, 106, 127-137.	3.0	12
148	Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline. Social Science and Medicine, 2016, 151, 167-172.	3.8	12
149	Protocol for a nationwide survey of primary health care in China: the China PEACE (Patient-centered) Tj ETQq1 1 0.784314 rgBT /Overlock 101 BMJ Open, 2017, 7, e016195.	1.9	12
150	Addressing the Challenges in Tonsillectomy Research to Inform Health Care Policy. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 943.	2.2	12
151	Risk factors for death or heart transplantation in single-ventricle physiology (tricuspid atresia,) Tj ETQq1 1 0.784314 rgBT /Overlock 101 Transplantation, 2019, 38, 739-747.	0.6	12
152	Organ Donation and Drug Intoxicationâ€“Related Deaths in the United States. New England Journal of Medicine, 2019, 380, 597-599.	27.0	12
153	Rebuilding Sudan's health system: opportunities and challenges. Lancet, The, 2020, 395, 171-173.	13.7	12
154	Increasing demand while decreasing costs of generic medicines. Lancet, The, 2000, 356, 1784-1785.	13.7	11
155	The contestable nature of health policy analysis. Health Economics (United Kingdom), 2005, 14, S3-S6.	1.7	11
156	EU competition law and health policy. , 2010, , 337-378.		11
157	How Can We Link General Medical and Behavioral Health Care? International Models for Practice and Policy. Psychiatric Services, 2015, 66, 775-777.	2.0	11
158	Structural equation model for estimating risk factors in type 2 diabetes mellitus in a Middle Eastern setting: evidence from the STEPS Qatar. BMJ Open Diabetes Research and Care, 2016, 4, e000231.	2.8	11
159	The Amsterdam Treaty and the Future of European Health Services. Journal of Health Services Research and Policy, 1998, 3, 65-67.	1.7	10
160	Genetic testing and insurance. Journal of the Royal Society of Medicine, 2001, 94, 57-60.	2.0	10
161	Information technology law and health systems in the European Union. International Journal of Technology Assessment in Health Care, 2004, 20, 498-508.	0.5	10
162	Global health financing towards 2030 and beyond. Health Economics, Policy and Law, 2017, 12, 105-111.	1.8	10

#	ARTICLE	IF	CITATIONS
163	Paying for the NHS. <i>BMJ: British Medical Journal</i> , 2000, 320, 197-198.	2.3	9
164	EMA and the evaluation of health-related quality of life data in the drug regulatory process. <i>International Journal of Technology Assessment in Health Care</i> , 2004, 20, 311-324.	0.5	9
165	The future of the NHS: no longer the envy of the world?. <i>Lancet, The</i> , 2018, 391, 1001-1003.	13.7	9
166	Parental migration and self-reported health status of adolescents in China: A cross-sectional study. <i>EClinicalMedicine</i> , 2020, 22, 100371.	7.1	9
167	An Initial Analysis of the Effects of a Long-Term Care Insurance on Equity and Efficiency: A Case Study of Qingdao City in China. <i>Research on Aging</i> , 2021, 43, 156-165.	1.8	9
168	Effective post-pandemic governance must focus on shared challenges. <i>Lancet, The</i> , 2022, 399, 1999-2001.	13.7	9
169	Will Managed Care Work in Europe?. <i>Pharmacoeconomics</i> , 1997, 11, 297-305.	3.3	8
170	Measuring equity of access to health care. , 2010, , 187-221.		8
171	EU competition law and public services. , 0, , 315-336.		8
172	Risk adjustment for performance measurement. , 2010, , 251-285.		8
173	Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 189-211.	2.1	8
174	The impact of primary health care and specialist physician supply on amenable mortality in Mexico (2000-2015): Panel data analysis using system-Generalized Method of Moments. <i>Social Science and Medicine</i> , 2021, 278, 113937.	3.8	8
175	Evaluation of progress toward universal health coverage in Myanmar: A national and subnational analysis. <i>PLoS Medicine</i> , 2021, 18, e1003811.	8.4	8
176	Evaluation of the NHS England evidence-based interventions programme: a difference-in-difference analysis. <i>BMJ Quality and Safety</i> , 2023, 32, 90-99.	3.7	8
177	Subjective Financial Hardship due to Medical Bills Among Patients With Heart Failure in the United States: The 2014-2018 Medical Expenditure Panel Survey. <i>Journal of Cardiac Failure</i> , 2022, 28, 1424-1433.	1.7	8
178	The Wanless report and decision-making in public health. <i>Journal of Public Health</i> , 2005, 27, 133-134.	1.8	7
179	International health system comparisons: from measurement challenge to management tool. , 0, , 641-672.		7
180	Public performance reporting on quality information. , 2010, , 537-551.		7

#	ARTICLE	IF	CITATIONS
181	EU regulatory agencies and health protection. , 2010, , 134-185.		7
182	Using composite indicators to measure performance in health care. , 2010, , 339-368.		7
183	'Avoidable' mortality: a measure of health system performance in the Czech Republic and Slovakia between 1971 and 2008. Health Policy and Planning, 2013, 28, 508-525.	2.7	7
184	An ethical appraisal of living-anonymous kidney donation using Adam Smith's Theory of Moral Sentiments. Health Policy, 2018, 122, 1212-1221.	3.0	7
185	NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances. International Journal of Technology Assessment in Health Care, 2020, 36, 426-433.	0.5	7
186	The "Netflix plus model": can subscription financing improve access to medicines in low- and middle-income countries?. Health Economics, Policy and Law, 2021, 16, 113-123.	1.8	7
187	End-of-Life Planning Depends on Socio-Economic and Racial Background: Evidence from the US Health and Retirement Study (HRS). Journal of Pain and Symptom Management, 2021, 62, 1198-1206.	1.2	7
188	Promoting innovation while controlling cost: The UK's approach to health technology assessment. Health Policy, 2022, 126, 224-233.	3.0	7
189	Performance measurement in primary care. , 2010, , 371-405.		6
190	Population health. , 2010, , 27-62.		6
191	Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 58-65.	4.0	6
192	Accelerated access to new drugs and technologies. BMJ: British Medical Journal, 2017, 359, j5387.	2.3	6
193	Time to strengthen capacity in infectious disease control at the European level. International Journal of Infectious Diseases, 2020, 99, 263-265.	3.3	6
194	Primary care and prescription drugs: coverage, cost-sharing, and financial protection in six European countries. Issue Brief (Commonwealth Fund), 2010, 82, 1-14.	0.9	6
195	Which policies effectively enable smoking cessation? Evidence from the European Union. International Journal of Social Economics, 2006, 33, 77-100.	1.9	5
196	Erring on the Side of Caution? The Heterogeneity of Public Perceptions of Biotechnology Applications in the European Union. Journal of Economic Issues, 2006, 40, 767-777.	0.8	5
197	Bioethical Implications of Globalization: An International Consortium Project of the European Commission. PLoS Medicine, 2006, 3, e43.	8.4	5
198	Patient-reported outcome measures and performance measurement. , 2010, , 63-86.		5

#	ARTICLE	IF	CITATIONS
199	Performance measurement in mental health services. , 2010, , 426-471.		5
200	The EU pharmaceuticals market: parameters and pathways. , 2010, , 635-682.		5
201	Lives cut short: socioeconomic inequities, homelessness, and cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 4021-4023.	2.2	5
202	Study design, result posting, and publication of late-stage cardiovascular trials. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 277-288.	4.0	5
203	Improving transparency and performance of private hospitals. <i>BMJ, The</i> , 2020, 368, m577.	6.0	5
204	Incentivising antibiotic research and development: is the UK's subscription payment model part of the solution?. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 162-163.	9.1	5
205	A County-Level Analysis of Socioeconomic and Clinical Predictors of COVID-19 Incidence and Case-Fatality Rates in Georgia, Marchâ€September 2020. <i>Public Health Reports</i> , 2021, 136, 626-635.	2.5	5
206	Financial Risk Protection and Unmet Healthcare Need in Russia. <i>International Journal of Health Policy and Management</i> , 2021, , .	0.9	5
207	Economic Aspects of Delivering Primary Care Services: An Evidence Synthesis to Inform Policy and Research Priorities. <i>Milbank Quarterly</i> , 2021, 99, 974-1023.	4.4	5
208	Are we heading for a two tier healthcare system in the UK?. <i>BMJ, The</i> , 2022, 376, o618.	6.0	5
209	Mental health and conspirasism in health care professionals during the spring 2020 COVID-19 lockdown in Greece. <i>Acta Neuropsychiatrica</i> , 2022, 34, 132-147.	2.1	5
210	The European Court of Justice and the free movement of patients in the European Union. <i>International Social Security Review</i> , 2003, 56, 3-29.	0.8	4
211	EU law and regulation of private health insurance. <i>Health Economics, Policy and Law</i> , 2007, 2, 117-124.	1.8	4
212	Are Feelings of Genetically Modified Food Politically Driven?. <i>Risk Management</i> , 2008, 10, 218-234.	2.3	4
213	Knowledge about Avian Influenza, European Region. <i>Emerging Infectious Diseases</i> , 2008, 14, 1956-1957.	4.3	4
214	Targets and performance measurement. , 0, , 509-536.		4
215	Health system productivity and efficiency. , 2010, , 222-248.		4
216	Incentives for health-care performance improvement. , 0, , 582-612.		4

#	ARTICLE	IF	CITATIONS
217	Systematic review of economic analyses in patient safety: a protocol designed to measure development in the scope and quality of evidence. <i>BMJ Open</i> , 2017, 7, e017089.	1.9	4
218	Why private health insurance?. , 2020, , 1-40.		4
219	Uncovering the complex role of private health insurance in Ireland. , 2020, , 221-263.		4
220	Regression to the increasingly mean?<i>Private health insurance in the United States of America</i>. , 2020, , 494-524.		4
221	Financial protection in health among the middle-aged and elderly: Evidence from the Greek economic recession. <i>Health Policy</i> , 2021, 125, 1256-1266.	3.0	4
222	Delayed medical care due to transportation barriers among adults with atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2022, 245, 60-69.	2.7	4
223	Low demand for substitutive voluntary health insurance in Germany. <i>Croatian Medical Journal</i> , 2002, 43, 425-32.	0.7	4
224	Performance measurement and professional improvement. , 0, , 613-640.		3
225	EU law and health professionals. , 0, , 589-634.		3
226	Private finance publicly subsidized: the case of Australian health insurance. , 2020, , 41-64.		3
227	Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 311-316.	0.5	3
228	U.S. Healthcare Insurance Market Concentration from 2001 to 2016: Increased Growth in Direct Written Premiums and Overall Decreased Market Consolidation. <i>Cureus</i> , 2020, 12, e7491.	0.5	3
229	The Impact of Managed Care on Clinical Research. <i>Pharmacoeconomics</i> , 1998, 14, 19-25.	3.3	2
230	Clinical surveillance and patient safety. , 2010, , 286-310.		2
231	Long-term care quality monitoring using the interRAI common clinical assessment language. , 0, , 472-506.		2
232	A national incident reporting and learning system in England and Wales, but at what cost?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 365-368.	1.4	2
233	Training the next generation of cardiovascular leaders in health policy and economics. <i>European Heart Journal</i> , 2017, 38, 3332-3335.	2.2	2
234	Costâ€Effectiveness of Cardiovascular, Obesity, and Diabetes Mellitus Drugs: Comparative Analysis of the United States and England. <i>Journal of the American Heart Association</i> , 2020, 9, e018281.	3.7	2

#	ARTICLE	IF	CITATIONS
235	The health and economic burden of antimicrobial resistance. , 2020, , 23-44.		2
236	Tackling antimicrobial resistance in the community. , 2020, , 45-70.		2
237	The role of vaccines in combating antimicrobial resistance. , 2020, , 181-206.		2
238	Private health insurance in Canada. , 2020, , 99-141.		2
239	The challenges of pursuing private health insurance in low- and middle-income countries: lessons from South Africa. , 2020, , 377-413.		2
240	Undermining risk pooling by individualizing benefits: the use of medical savings accounts in South Africa. , 2020, , 414-445.		2
241	Accountability and transparency are vital in a pandemic response. Journal of General and Family Medicine, 2021, 22, 113-114.	0.8	2
242	“Erring on the side of rare events” A behavioural explanation for COVID-19 vaccine regulatory misalignment. Journal of Global Health, 2021, 11, 03080.	2.7	2
243	The cost of prejudice for poorer people: understanding experiences of discrimination in cardiac arrest care. European Heart Journal, 2021, 42, 870-872.	2.2	2
244	Understanding personal health budgets. BMJ, The, 2020, 368, m324.	6.0	2
245	What has the 2020 Tokyo Olympic and Paralympic Games taught global health on sporting mass gatherings under COVID-19 pandemic?. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101001.	1.4	2
246	Clinical and Economic Profile of Homeless Young Adults with Stroke in the United States, 2002 “ 2017. Current Problems in Cardiology, 2022, , 101190.	2.4	2
247	Measuring clinical quality and appropriateness. , 0, , 87-113.		1
248	Overestimating the Benefit of Cancer Drugs“Reply. JAMA Oncology, 2017, 3, 1738.	7.1	1
249	Time to address the plight of the people of northeastern Syria. Lancet, The, 2019, 393, 1394-1396.	13.7	1
250	Association between provincial income levels and drug prices in China over the period 2010“2017. Social Science and Medicine, 2020, 263, 113247.	3.8	1
251	Private health insurance in Brazil, Egypt and India. , 2020, , 65-98.		1
252	Integrating public and private insurance in the Israeli health system: an attempt to reconcile conflicting values. , 2020, , 264-303.		1

#	ARTICLE	IF	CITATIONS
253	Consumer-driven health insurance in Switzerland, where politics is governed by federalism and direct democracy. , 2020, , 446-493.		1
254	Tackling antimicrobial resistance in the food and livestock sector. , 2020, , 99-124.		1
255	Can the US COVID-19 Response Advance Equity in Cardiovascular Health?. European Heart Journal, 2021, 42, 3897-3899.	2.2	1
256	United Kingdom: Health System Review.. Health Systems in Transition, 2022, 24, 1-194.	5.2	1
257	Clinical practice and the UK Human Rights Act 1998: protecting individual rights in the interest of the wider community. Clinical Medicine, 2001, 1, 464-469.	1.9	0
258	Attribution and causality in health-care performance measurement. , 0, , 311-338.		0
259	Chronic care. , 0, , 406-425.		0
260	Developing information technology capacity for performance measurement. , 0, , 552-581.		0
261	Elective cardiovascular care in the era of the COVID-19 pandemic: managing tragic choices. BMJ Open Quality, 2020, 9, e001069.	1.1	0
262	Regulating private health insurance:France's attempt at getting it all. , 2020, , 142-179.		0
263	Statutory and private health insurance in Germany and Chile: two stories of coexistence and conflict. , 2020, , 180-220.		0
264	Private health insurance in Japan, Republic of Korea and Taiwan, China. , 2020, , 304-324.		0
265	The role of private health insurance in financing health care in Kenya. , 2020, , 325-348.		0
266	Private health insurance in the Netherlands. , 2020, , 349-376.		0
267	Health savings accounts in the United States of America. , 2020, , 525-551.		0
268	Tackling antimicrobial resistance in the hospital sector. , 2020, , 71-98.		0
269	Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. , 2020, , 125-154.		0
270	Ensuring innovation for diagnostics for bacterial infection to combat antimicrobial resistance. , 2020, , 155-180.		0

#	ARTICLE	IF	CITATIONS
271	The UK Health and Care Bill: failure to address fundamental issues of coverage and funding. <i>Lancet</i> , 2021, 397, 1259.	13.7	0
272	Clinical negligence cases in the English NHS: uncertainty in evidence as a driver of settlement costs and societal outcomes. <i>Health Economics, Policy and Law</i> , 2021, , 1-16.	1.8	0
273	The Coverage in England of US-Approved Cancer Drugsâ€™Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1263.	5.1	0
274	The role of civil society in tackling antimicrobial resistance. , 2020, , 207-240.		0
275	DISCRETE CHOICE EXPERIMENT TO INVESTIGATE PREFERENCES FOR INCENTIVES TO PROMOTE ANTIMICROBIAL RESEARCH & DEVELOPMENT. <i>Journal of Global Antimicrobial Resistance</i> , 2022, , .	2.2	0
276	Patient-reported disruptions to cancer care in the U.S. during the COVID-19 pandemic: A national cross-sectional study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10561-10561.	1.6	0
277	Challenges of balancing international health and travel in a pandemic: Lessons from the French Caribbean during COVID-19 passports. <i>The Lancet Regional Health Americas</i> , 2022, 13, 100327.	2.6	0